A Phase 3 interventional study of Brexanolone and Placebo in Acute Respiratory Distress Syndrome and COVID-19, sponsored by Sage Therapeutics. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-19.
Sponsored by Sage Therapeutics (part of Supernus Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 160th largest by enrollment of the 250 interventional ones that give a count, is one of 63 that started in 2020, is one of 36 in phase 3, and was the 239th registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Implicit Bioscience · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 63 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sage Therapeutics, one of the names counted as Supernus Pharmaceuticals, Inc.. Under that name alone:
Sage Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Supernus Pharmaceuticals, Inc. has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous intravenous (IV) infusion of brexanolone-matching placebo.
Drug: Placebo
Participants receiving mechanical ventilation as standard of care were randomized to receive a 60-hour single continuous IV infusion of brexanolone at 70 micrograms per kilogram per hour (mcg/kg/h) for 58 hours followed by a 2-hour taper of brexanolone at 35 mcg/kg/h.
Drug: Brexanolone
Administered as IV infusion.
Also known as: Allopregnanolone, Zulresso, SAGE-547
Administered as IV infusion.
Percentage of Participants Who Are Alive and Free of Respiratory Failure at Day 28
Respiratory failure is defined based on resource utilization, requiring at least one of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates \>20 liter/minute with fraction of delivered oxygen \>=0.5), noninvasive positive pressure ventilation, and extracorporeal membrane oxygenation (ECMO). Percentage of participants who were alive and free of respiratory failure at Day 28 were reported in this outcome measure.
Time frame: Day 28
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a participant administered with a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of an IP whether or not related to the product. An AE can include any undesirable medical condition, even if no study treatment has been administered. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.
Time frame: From first dose of investigational product up to end of study (up to Day 40)
Number of Participants Who Died Through Day 28
All cause mortality was reported up to Day 28 in this outcome measure.
Time frame: From screening up to Day 28
Participants were enrolled in the study at 9 centers in the United States from 18 December 2020 to 01 July 2021.
| Milestone | Placebo | Brexanolone |
|---|---|---|
| Started | 15 | 14 |
| Safety analysis set | 14 | 14 |
| Full analysis set | 14 | 14 |
| Completed | 13 | 13 |
| Not completed | 2 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
Respiratory failure is defined based on resource utilization, requiring at least one of the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates \>20 liter/minute with fraction of delivered oxygen \>=0.5), noninvasive positive pressure ventilation, and extracorporeal membrane oxygenation (ECMO). Percentage of participants who were alive and free of respiratory failure at Day 28 were reported in this outcome measure.
| percentage of participants | Placebo | Brexanolone |
|---|---|---|
| Percentage of Participants Who Are Alive and Free of Respiratory Failure at Day 28 | 23.1 | 23.1 |
An adverse event (AE) is any untoward medical occurrence in a participant administered with a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of an IP whether or not related to the product. An AE can include any undesirable medical condition, even if no study treatment has been administered. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.
| Participants | Placebo | Brexanolone |
|---|---|---|
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) | 13 | 14 |
All cause mortality was reported up to Day 28 in this outcome measure.
| Participants | Placebo | Brexanolone |
|---|---|---|
| Number of Participants Who Died Through Day 28 | 6 | 8 |
Collected over From screening up to end of study (up to Day 40). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 7/14 (50%) | 8/14 (57.1%) | 11/14 (78.6%) |
| Brexanolone | 8/14 (57.1%) | 8/14 (57.1%) | 11/14 (78.6%) |
| Event | Placebo | Brexanolone |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/14 | 4/14 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/14 | 3/14 |
| EncephalopathyNervous system disorders | 0/14 | 2/14 |
| Septic shockInfections and infestations | 2/14 | 0/14 |
| Endotracheal intubationSurgical and medical procedures | 2/14 | 0/14 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/14 | 1/14 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/14 | 1/14 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 1/14 | 0/14 |
| Atrial fibrillationCardiac disorders | 1/14 | 1/14 |
| Acute myocardial infarctionCardiac disorders | 0/14 | 1/14 |
| Event | Placebo | Brexanolone |
|---|---|---|
| Septic shockInfections and infestations | 0/14 | 4/14 |
| DeliriumPsychiatric disorders | 0/14 | 3/14 |
| HypertensionVascular disorders | 3/14 | 1/14 |
| HypernatraemiaMetabolism and nutrition disorders | 3/14 | 0/14 |
| ConstipationGastrointestinal disorders | 2/14 | 2/14 |
| HypotensionVascular disorders | 2/14 | 1/14 |
| BlisterSkin and subcutaneous tissue disorders | 0/14 | 2/14 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/14 | 0/14 |
| Alanine aminotransferase increasedInvestigations | 2/14 | 0/14 |
| Aspartate aminotransferase increasedInvestigations | 2/14 | 0/14 |
FAS included all randomized participants who initiated IP (brexanolone or placebo).
| Age, Continuous(years) | Placebo | Brexanolone | Total |
|---|---|---|---|
| Mean | 62.6 ± 9.81 | 58.2 ± 12.79 | 60.4 ± 11.40 |
| Sex: Female, Male(Participants) | Placebo | Brexanolone | Total |
|---|---|---|---|
| Female | 6 | 8 | 14 |
| Male | 8 | 6 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Brexanolone | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 11 | 10 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Brexanolone | Total |
|---|---|---|---|
| Race — Asian | 1 | 1 | 2 |
| Race — Black or African American | 2 | 1 | 3 |
| Race — White | 10 | 11 | 21 |
| Race — Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jul 2021, 6 months.
Results were first posted in Jul 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Respiratory Distress Syndrome →